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Molecular stratification of early breast cancer identifies drug
targets to drive stratified medicine
Jane Bayani1, Cindy Q. Yao1, Mary Anne Quintayo1, Fu Yan1, Syed Haider1, Alister D’Costa1, Cassandra L. Brookes2,
Cornelis J. H. van de Velde3, Annette Hasenburg4, Dirk G. Kieback5, Christos Markopoulos6, Luc Dirix7, Caroline Seynaeve8, Daniel Rea2,
Paul C. Boutros1,9 and John M. S. Bartlett1,2,9
Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone.
However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk
women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies.
Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial
pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A
panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer
pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-
treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI
3.53–7.22, p = 7.51 × 10−19). This risk signature was also found to perform better than current multiparametric tests. When the 95-
gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant
chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10−28). Functional gene interaction
analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine
signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the
identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with
these targeted therapies.
npj Breast Cancer  (2017) 3:3 ; doi:10.1038/s41523-016-0003-5
INTRODUCTION
Despite significant improvements in the treatment of early
estrogen receptor positive (ER+) breast cancer, there are ongoing
clinical challenges. Targeted anti-endocrine therapies have
reduced mortality over the last 30–40 years,1, 2 but ER+ disease,
which comprises 80% of breast cancers, still leads to the majority
of deaths from early breast cancer.3 Multiparametric gene
assays are used increasingly to guide clinical treatment decisions.4
Most prognostic tests provide an estimate of relapse risk following
the treatment for ER+ breast cancer, but still lack predictive value
for novel targeted treatment options.2, 4 These multiparametric
tests, which include OncotypeDx® (Genomic Health Inc.),5, 6
Prosigna™ (NanoString Technologies, Inc.),7–9 MammaPrint®
(Agendia Inc.),10, 11 Breast Cancer Index (BioTheranostics Inc.),12, 13
and EndoPredict (Sividon Diagnostics GmbH),14 all provide
broadly similar clinical utility.15, 16 Although each is derived from
RNA abundance studies, there are surprisingly few overlapping
genes between different RNA signatures.17 Prat et al., demon-
strated in silico that combined signatures may more accurately
predict outcome; leading to greater clinical significance.18 None-
theless, despite a decade of development of multiple residual risk
signatures, progress towards stratified or targeted medicine has
not been markedly accelerated by these tests. None of the existing
tests have identified actionable targets which might form the
basis for the next generation of stratified medicine approaches.
Using the Tamoxifen and Exemestane Adjuvant Multinational
trial (TEAM) pathology cohort,19 comprised of 3825 hormone-
receptor positive (ER+ and/or PgR+) cases and including 477
(13%) HER2-positive cases, we have discovered and validated a
novel 95-gene signature of residual risk, which has the potential to
markedly improved risk stratification in the context of endocrine-
treated patients. Moreover, this gene signature has also revealed
potentially druggable targets, thus moving closer to the vision of
stratification to targeted therapies for such high-risk patients.
RESULTS
The RNA abundance profiles of all genes were generated for 3825
patients. Of patients who had complete therapy information, 2549
were treated with endocrine therapies alone, while 1275 also
received adjuvant chemotherapy. The endocrine-treated only
patients were divided into a 576-patient training cohort (n = 67
events), and a 1973-patient validation cohort (n = 253 events),
which was used for signature discovery and validation,
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respectively. To test the prognostic ability of the signature, which
was trained and validated in the endocrine-treated patients, to
patients who were treated with adjuvant chemotherapy, the
signature was then modeled against all patients in the validation
cohort and adjusted for adjuvant chemotherapy (n = 3035). The
median follow-up in each cohort was 7.51 and 6.21 years,
respectively. The clinical characteristics of the endocrine-treated
training and validation cohorts are described in Table 1. The
clinical characteristics of the entire cohort of 3825 patients are
summarized in Supplementary Table 1. High tumor grade, nodal
status, pathological size, and HER2 IHC status were univariately
prognostic in both training and validation cohorts (Table 1 and
Supplementary Table 1).
Identification and validation of a residual risk signature following
endocrine treatment
Univariate assessment of the original gene list of 165 genes
identified 95 genes which were prognostically significant in the
endocrine-treated only patients (Supplementary Table 2, Supple-
mentary Fig. 1). The 95 genes were aggregated into functional
modules and used to train a residual risk model. Modeling of the
module dysregulation (MDS) scores (as described in the Supple-
mentary Methods) generated from these 95 genes, with and
without clinical covariates, resulted in a final refined signature that
included nodal status as the only clinical covariate (Fig. 1). This risk
model was found to be comparable in the training cohort when
the 95-gene signature was used, without clinical covariates
(HRhigh = 4.05, 95% CI 2.25–7.3, p = 3.28 × 10
−6; 10-fold cross
validation ) and when clinical co-variates such as age, tumor
grade, pathological tumor size, and nodal status were included
(HRhigh = 2.74, 95% CI 1.61–4.65, p = 2.06 × 10
−4; 10-fold cross
validation) (Supplementary Fig. 2). When dichotomized around
the median and applied to the validation set, the resulting 95-
gene signature was a robust predictor of DFRS following
endocrine treatment (HRhigh = 5.05, 95% CI 3.53–7.22, p = 7.51 ×
10−19, Fig. 1a). As with the training set, similar results were
obtained when all clinical covariates were included in the model
of the validation cohort (HRhigh = 5.56, 95% CI 3.85–8.03, p =
5.75 × 10−20, Supplementary Fig. 3). When samples were split into
quartiles (Fig. 1b), the signature identified patients were at a very
low risk (<5% DRFS at 10 years). The continuous risk scores from
this signature were directly correlated with the likelihood of
recurrence at 5(Fig. 1c) and 10-years (Fig. 1d), with a higher risk
score associated with a markedly higher likelihood of a metastatic
event.
Performance of the 95-gene signature of residual risk in the
presence of adjuvant chemotherapy
To determine whether the 95-gene residual signature continued
to be prognostic amongst patients who also received adjuvant
chemotherapy, the model was applied to all patients in the
validation cohort (with and without chemotherapy), but stratified
to chemotherapy (Supplementary Fig. 4A and B). The results
showed that the 95-gene signature was still prognostic in this
subset of patients (HRhigh = 4.7, 95% CI 3.61-6.28, p = 2.53× 10
−28).
Stratifying according to adjuvant chemotherapy showed no
difference in the DRFS between patients defined as low or high
risk by the signature (Supplementary Fig. 4C).
Performance of the 95-gene signature of residual risk when
adjusted for HER2 status
To determine whether the 95-gene residual risk signature
remained prognostic in both HER2-positive and HER2-negative
patients, the model was applied to patients in the validation
cohort who did not receive any additional adjuvant chemotherapy
and results stratified by HER2-status (Supplementary Fig. 5). When
the model was applied to all patients and stratified by HER2-status
(Supplementary Fig. 5A), patients identified as low-risk by the 95-
gene signature, showed no significant difference in DRFS between
HER2-positive or HER-2 negative patients (p = 0.78). Similarly, for
patients identified as high-risk, we observed no statistically
significant difference in DRFS between HER2-positive or HER2-
negative patients (p = 0.09), although we did observe that HER2-
positive patients showed a trend for worse outcome. Overall, the
signature can differentiate high-risk from low-risk individuals
within either HER2-positive (HR = 5.17; 95% CI: 1.25–21.38; p =
0.023) or HER2-negative (HR = 4.75; 95% CI: 3.23–6.97; p = 2.01 ×
10−15) patient subsets.
Performance of the 95-gene signature to multiparametric tests
Using the NanoString RNA abundance data, risk scores from
current multiparametric test were generated and are summarized
in Fig. 2a and Supplementary Table 3, along with known
prognostic clinical factors. Molecular intrinsic subtyping results
are also shown (Fig. 2a). While there exists a common group of
Table 1 Clinical characteristics of the endocrine-treated patients
Training Validation
HR 95% CI P-value N HR 95% CI P-value N
Age (<55) 1.791 0.44–7.32 0.417 576 0.856 0.52–1.40 0.535 1974
Nodal Status
0 vs. 1–3 1.372 0.81–2.33 0.240 567 1.323 0.98–1.78 0.066 1925
0 vs. 4–9 3.314 1.46–7.53 0.004 4.021 2.77–5.83 1.916 × 10−13
0 vs. 10+ 4.973 1.75–14.10 0.003 6.562 4.17–10.34 4.907 × 10−16
Pathological Size (Categorical)
≤2 vs. (>2 cm & ≤5 cm) 1.953 1.19–3.20 0.008 576 2.148 1.63–2.83 5.765 × 10−08 1972
≤2 vs. >5 3.096 0.94–10.17 0.063 2.755 1.75–4.33 1.117 × 10−5
Pathological Size (Continuous) 1.163 1.06–1.27 0.001 560 1.311 1.21–1.42 9.401 × 10−12 1963
Grade
1 vs. 2 1.835 0.56–5.99 0.315 563 1.433 0.90–2.29 0.131 1869
1 vs. 3 3.341 1.02–10.93 0.046 2.606 1.64–4.15 5.452 × 10−5
HER2 2.31 1.33–4.02 0.003 564 1.835 1.32–2.55 2.745 × 10−4 1890
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high-risk and low-risk patients across all tests, there are large
numbers of patients with discordant results (Fig. 2a, Supplemen-
tary Table 4). When compared to the risk scores generated based
on the commercial tests (Fig. 2b, Table 2), our 95-gene signature
performed better than these multiparametric tests, with an Area
Under the Curve (AUC) of 0.76. The differences in AUC between
the commercial tests and the 95-gene risk score were found to be
statistically significant (Table 3). The summary of commercial-like
risk scores across the validation cohort, in addition to the overall
concordance between the tests are shown in Supplementary
Tables 3 and 4, with Kaplan–Meier survival plots for each of the
commercial or academic risk stratification tests shown in
Supplementary Fig. 6 and described further in the Supplementary
Data. Overall, each test, as recapitulated using our NanoString RNA
abundance data, could discriminate with statistical significance
(Supplementary Data and Supplementary Fig. 6), between patients
at low or high risk for recurrence.
Identification of druggable targets in the 95-Gene signature and
implications for stratified precision medicine
Six significant network modules were identified using the
Reactome Functional Interaction (FI) tool, comprising 52 of 95
genes in the signature (Fig. 3a, Table 4). Modules 1, 3, and 4
Fig. 1 Kaplan–Meier survival plots of the 95-gene residual risk signature in the TEAM pathology cohort. a Survival curves based on the
prognostic model including nodal status applied to the validation cohort of patients receiving only endocrine therapy. b Risk score estimates
shown in A grouped as quartiles with each group compared against Q1. Hazard ratios were estimated using Cox proportional hazards model
and significance of survival difference was estimated using the log-rank test. c Distribution of patient risk scores in the TEAM Validation cohort
showing the predicted 5 year recurrence probabilities (solid line) and 95% CI (dashed lines) as a function of patient risk score. Vertical dashed
black line indicates training set median risk score. d Distribution of patient risk scores in the TEAM Validation cohort showing the predicted 10
year recurrence probabilities (solid line) and 95% CI (dashed lines) as a function of patient risk score. Vertical dashed black line indicates training
set median risk score
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Fig. 2 Comparison of the 95-gene residual risk signature to multi-parametric tests in the validation cohort. a Summary of patients assessed in
the validation cohort using the 95-gene residual risk signature and other current multiparametric tests in addition to clinical covariates.
Patient samples were ranked according to overall concordance, with all patients called as high-riskor low-risk, across all tests organized at the
bottom and top of the heatmap, respectively. Standard clinical covariates such as HER2 status, age, grade, nodal status, stage are included.
Molecular subtyping based on the PAM50/Prosigna-like test is also shown. b As performance indicator, area under the receiver operating
characteristic (AUC) curves for each multiparametric test is also shown. All patients represented are those who only received endocrine
treatment
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included genes involved in mitosis (FDR < 5.0 × 10−4), cell cycle
(FDR < 3.33 × 10−4), as well as pathways associated with cell cycle
checkpoints (FDR = 0.0001). Module 2 included genes and path-
ways involved in receptor-tyrosine signaling including Erb-
Receptor (ERBB) pathway signaling (FDR < 6.66 × 10−5), PI3K-AKT
signaling (FDR < 8.33 × 10−5), p53 signaling (FDR < 5.00 × 10−4),
and apoptosis (FDR = 0.00479). Normalized expression for the
individual genes (Supplementary Table 5) within the modules
showed that all genes within Modules 1, 3, and 4 were more
highly expressed among patients classed as high-risk (Supple-
mentary Table 5; Wilcoxon rank-sum test). These differences were
found to be statistically significant (Supplementary Table 5). As
individual modules, they were statistically significant predictors of
outcome (Fig. 3b). Though not statistically significant, a higher
AUC was observed when using all 95 genes together as a residual
risk signature set and hence was carried over as the final list
(HRhigh = 5.05, 95% CI 3.53–7.22, p = 7.51 × 10
−19). Module 1,
comprised of genes largely associated with mitosis and regulation
of the cell cycle such as BIRC5, BUB1B, CCNB1, and PTTG1
(Table 4); could classify patients in the validation cohort as low-risk
or high-risk (HRhigh = 3.01, 95% CI 2.27-4.0, p = 1.81 × 10
−14).
Similarly, genes from Modules 3 and 4, including Aurora Kinase
A, CDK1, CCND1, CCNE2, CDC6, and PLK1, classified patients in
low-risk and high-risk categories: HRhigh = 3.3, 95% CI 2.47–4.42, p
= 9.82 × 10−16 and HRhigh = 3.84, 95% CI 2.83–5.21, p = 5.12 ×
10−18, respectively (Fig. 3b). Normalized RNA abundance within
Module 2 was mixed (Supplementary Table 5), with some showing
decreased expression among high-risk patients (i.e. TP53 and
BCL2), and others showing increased expression (i.e. CCNE1 and
RRM2); but when modeled as a group, Module 2 could also
identify patients with worse prognosis (HRhigh = 4.03, 95% CI
2.98–5.45, p = 1.03 × 10−19). Finally, Module 5, comprising of CDH3
and MMP9 was also a significant predictor of DRFS (HRhigh = 1.33,
95% CI 1.04–1.71, p = 0.022), as well as Module 6 comprising two
genes; KPNA2 and KRT8 (HRhigh = 2.65, 95% CI 2.01–3.49, p =
5.43 × 10−12).
Using the Integrity Compound Search (Thomson Reuters) for
the genes within these modules, a number of targeted
compounds were identified as being currently used in the clinic
for treatment of breast cancer or other neoplasms; or in phase II
and/or phase III development (https://clinicaltrials.gov/) (Fig. 3,
Supplementary Table 6). Among these compounds, a number
have potential for stratified use in the early luminal breast cancer
setting (Table 4) for those deemed high-risk by our classifier.
Therefore, these compounds hold potential for repurposing
targeted therapies to early luminal breast cancers (Supplementary
Fig. 7).
DISCUSSION
Relapse following endocrine treatment remains a significant
clinical challenge, as more women die following treatment for
ER+ disease than for any other breast cancer subtype.3 Therefore,
there is an ongoing need to identify women who are at risk for
relapse following anti-endocrine therapy. More importantly,
simultaneously identifying targets for future therapeutic interven-
tion and the means to effectively stratify women to such targeted
therapies will improve the clinical management of these patients,
and potentially reducing their overtreatment, or conversely
identifying patients who may be currently undertreated. Using
3825 patients from the TEAM pathology cohort, we are able to
derive a signature that both significantly improves risk stratifica-
tion and identifies genes for which there are drugs currently in
use, or under evaluation (https://clinicaltrials.gov/) in other
malignancies. These patients could potentially be matched to
the specific functional modules within this 95 gene signature
(Table 4, Supplementary Table 6). As alluded to by the prognostic
capacity of the individual modules (Fig. 3), this approach has the
potential to better stratify patients to existing targeted therapies
based on the molecular drivers of their cancer, and/or to novel/
putative targets for in vitro validation studies (Supplementary
Fig. 7). Despite the fact that our commercial risk score and subtype
classification was derived based on NanoString RNA abundance
Table 2 Performance of the 95-gene residual risk signature and multiparametric tests in the validation cohort
HR HR.95L HR.95U P N AUC
95-Gene Signature 5.045 3.528 7.215 7.51 × 10−19 1924 0.76
MammaPrint-like 3.631 2.765 4.767 1.66 × 10−20 1973 0.72
Prosigna-like 3.49 2.592 4.699 1.75 × 10−16 1971 0.70
IHC4-RNA 3.475 2.346 5.148 5.11 × 10−10 1973 0.72
Genomic Grade Index-like 3.118 2.341 4.153 7.51 × 10−15 1973 0.67
OncotypeDX-like 2.969 2.232 3.948 7.37 × 10−14 1973 0.71
IHC4-Protein 2.398 1.851 3.108 3.72 × 10−11 1855 0.68
Table 3 Statistical Differences in AUC between multiparametric tests and the 95-gene residual risk signature
Genomic Grade Index
—like
IHC4-
Protein
Prosigna-like OncotypeDX-like IHC4-RNA MammaPrint—like
IHC4-Protein 6.88 × 10−1
Prosigna-like 3.53 × 10−1 8.81 × 10−1
OncotypeDX-like 2.04 × 10−2 8.01 × 10−2 8.84 × 10−2
IHC4-RNA 4.16 × 10−3 4.28 × 10−2 2.23 × 10−2 8.11 × 10−1
MammaPrint-like 2.21 × 10−3 5.78 × 10−2 1.21 × 10−2 7.81 × 10−1 9.50 × 10−1
95-Gene Signature 2.83 × 10−9 4.02 × 10−5 3.02 × 10−8 5.10 × 10−3 4.25 × 10−3 2.98 × 10−3
Molecular stratification of early breast cancer
J Bayani et al
5
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2017)  3 
Module 1 Module 2
Module 3 Module 4
Module 5 Module 6
B
A
Molecular stratification of early breast cancer
J Bayani et al
6
npj Breast Cancer (2017)  3 Published in partnership with the Breast Cancer Research Foundation
profiling, our work confirmed the recent findings of the UK-
OPTIMA prelim trial17 that most current breast cancer multi-
parametric risk tests provide broadly equivalent risk information
for a population of women with ER+ breast cancers (Supplemen-
tary Fig. 6), but can exhibit discordance between tests at the
individual patient level (Fig. 2, Supplementary Tables 3 and 4).
However, while efforts are being made to identify those patients
who may be sensitive to current standard cytotoxic chemothera-
pies, we must also look to the promise of targeted therapies
against the molecular drivers of these high-risk patients as
revealed by the genes in the signature.
While current multiparametric tests can identify those who may
benefit from current adjuvant chemotherapy regimens, none of
these tests predicts response to a drug-specific chemotherapy.
This challenge is hampered by the identification of driver
pathways in addition to the complexities of both global and
individual chemotherapeutic response. Using the information
generated by this data we envision a model for future prospective
clinical trial design through the examination and validation of the
drugs targeting the gene modules comprising the 95-gene
signature (Supplementary Fig. 7, Supplementary Table 6). In this
way, genes associated with the G2/M checkpoint, as identified in
Module 1, such as BIRC5 (Survivin), could be targeted. Indeed
YM155, a Survivin suppressor, was recently evaluated in the
metastatic breast cancer setting in combination with docetaxel in
a phase II, multicenter, open-label, 2-arm study.20 However, the
lack of up-front patient stratification for YM155 benefit likely
contributed to the finding of no significant benefit in its addition
to docetaxel, thus obscuring the potential benefit of targeting this
pathway. While known to be overexpressed in breast cancers, the
relatively higher expression of BIRC5 observed among our high-
risk patients (q = 1.37× 10−178) (Supplementary Table 5) suggests
there is a tipping point of mRNA abundance leading to increased
risk. We observed that all genes within Modules 1, 3, and
4 showed a higher expression among patients at higher risk for
relapse which were statistically significant (Supplementary
Table 5), reflecting the prominent role of cell cycle and
proliferation in breast cancer pathogenesis. We see that Module
3 is characterized by pathways involving late mitotic events. The
overexpression of CDK1 offers a theranostic target, with the use of
Dinacilib or similar molecules, currently under evaluation in phase
III trials (Supplementary Table 6). Regaining cell cycle and mitotic
checkpoint control is another attractive mechanism for directed
therapies, with theranostic targets such as PLK1 (Fig. 3), being
treated with inhibitors in the preclinical and clinical setting.21, 22
The regulation of S-phase and DNA replication pathways of
Module 4, including CCND1, supports the potential stratification of
patients to Palbociclib or other CDK inhibitors (Supplementary
Table 6). Findings for the PALOMA-1 trial23 resulted in approval for
Palbociclib (CDK4/6 inhibitor) in combination with Letrozole in the
metatstatic breast cancer setting; paving the way for the
randomization of high-risk patients with ER+/HER2-cancer and
Fig. 3 Signaling modules within the 95-gene residual risk signature. a Summary of REACTOME interactions amongst the genes of the 95-gene
residual risk signature. Six major interaction modules comprising 52 genes were identified from the 95-gene residual risk signature.
Relationships between genes, between and within modules, are shown by connecting lines. Solid lines with arrows indicate known and direct
positive relationships. Solid lines ending in a perpendicular line indicate a known negative regulatory relationship. Dotted lines indicate
relationships linked by other genes. Genes with red circles indicate gene targets for which there are known targeted therapies or at phase II/III
development based on the Integrity compound search tool (Thompson Reuters) and ClinicalTrials.gov (https://clinicaltrials.gov/).
b Kaplan–Meier survival curves (left) for each module are shown, and representing the validation cohort. To the right of each Kaplan–Meier
curve are risk score estimates grouped as quartiles with each group compared against Q1. Hazard ratios were estimated using Cox
proportional hazards model and significance of survival difference was estimated using the log-rank test. All patients represented are those
who only received endocrine treatment
Table 4 Summary of pathway modules comprising the 95-gene residual risk signature
Module Gene List Pathways in Modules Putative Targeted Therapy a (Gene Target)
1 BIRC5 BUB1B CCNB1 CCNB2
CDC20 CENPA CENPF ESPL1 KIF2C
MAD2L1 NDC80 NUF2 PTTG1
STMN1
Mitotic Metaphase and Anaphase, Mitotic
Prometaphase, Cell cycle, Mitotic G2-G2/M phases,
Aurora A and B signaling, FOXM1 transcription
factor network, Oocyte meiosis, APC/C-mediated
degradation of cell cycle proteins, PLK1 signaling
events, Cell Cycle Checkpoints,
Gataparsen (BIRC5)
2 BAG1 BCL2, CCNE1 EGFR, ERBB3
ERBB4 FGF18 GSK3B MAPT MDM2
RRM2 TP53 TYMS
p53 signaling pathway, ERBB-family signaling,
PIK3CA-AKT signaling, Aurora A signaling, PLK
signaling, cell-cycle checkpoints, apoptotic
signaling. AKT-signaling, FGFR signaling, PDGF
signaling
Oblimersen Sodium (BCL2), Venetoclax (BCL2),
Obatoclax Mesylate (BCL2), Navitoclax (BCL2),
Patritumab (ERBB3), Sapitinib (ERBB3), Afatinib
(ERBB4), Neratinib (ERBB4), Dacomitinib (ERBB4),
Gefitinib (EGFR), Erlotinib (EGFR), Lapatinib
(EGFR), Pan-FGFR inhibitor (AP24534, FGF18)
3 ASPM AURKA CCNE2 CDK1 CEP5
ECT2 NEK2 PLK1 PRC1 RACGAP1
UBE2C
PLK1 signaling, Cell cycle checkpoints, Mitotic
telophase and cytokinesis, Mitotic telophase and
anaphase, FOXM1 transcription
Diniciclib (CDK1), Rigosertib sodium (PLK1),
Volasertib (PLK1)
4 CCND1 CDC6 LIN9 MCM10 MCM2
MCM6 MYBL2 ORC6, RFC4 UBE2T
S-phase, Regulation of DNA replication, Cell cycle,
p53 signaling, M/G1 transition
Palbociclib (CCND1)
5 CDH3 MMP9 Alzheimer disease-presenilin pathway, role of ran in
mitotic spindle regulation
6 KPNA2 KRT8 role of ran in mitotic spindle regulation, Regulation
of cytoplasmic and nuclear SMAD2/3 signaling
Pathways chosen with False Discovery Rate (FDR) p< 0.001
aCompound search conducted using Thomson Reuters IntegritySM and ClinicalTrials.gov (https://clinicaltrials.gov/)
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residual disease, in the PENELOPE-B trial. While promising in the
late and metastatic setting, CDK inhibitor use in the early breast
cancer setting has not yet been adequately assessed, nor is there a
validated method to stratify patients who would most benefit
from this treatment. Interestingly, recent in vitro evidence of
synergy between palbociclib with tamoxifen showed resensitiza-
tion to tamoxifen in ER-resistant cell lines,24 suggesting that the
identification of those who may be ER-resistant, could experience
greater benefit with the use combined use of endocrine therapy
and a CDK inhibitor. Genes of Module 2 are characterized by
receptor tyrosine kinase signaling, apoptosis and control of the
cell cycle have druggable targets among the members of ERBB-
family of genes. Anti-HER therapies are effective in ERBB2/HER2-
positive patients, but crosstalk between other members of the
Epidermal Growth Factor Receptor (EGFR)/ERBB family suggest the
aberrant expression of members aside from ERBB2/HER2 could
justify their use in the absence of HER2 amplification. EGFR
inhibitors such as gefitinib and laptinib have shown efficacy in
other malignancies, but only moderate success in breast cancer,
suggesting that an improved method of patient selection is
required to identify those who would benefit the most. Interest-
ingly, 296/342 (86.5%) HER2-enriched-like patients were identified
as high-risk by our classifier. However, with 33.8% of HER2-
enriched-like patients possessing confirmed HER2 gene amplifica-
tion or protein over-expression, these results suggest some
patients may benefit from therapy targeting the ERBB-family
and associated pathways. In fact, the 95-gene signature was still
prognostic irrespective of ERBB2/HER2-status, in this population of
patients that pre-dates the use of anti-ERBB2/HER2 therapies
(Supplementary Fig. 5). Moreover, while ERBB3 and ERBB4 were
found to be univariately prognostic and part of the final signature,
ERBB2/HER2 expression was not (Supplementary Table 2). This
data would suggest that in current clinical practice, a number of
our ERBB2/HER2-positive, low-risk patients would have received
anti-ERBB2/HER2 therapies, resulting with an outcome potentially
no better than ERBB2/HER2-negative patients. With respect to
high-risk patients who were also ERBB2/HER2-positive, anti-ERBB2/
HER2 treatment would have some benefit to a subset in this
group, but it is clear that there are other molecular drivers of
recurrence in this high-risk population. Downstream pathways of
ERBB, like PIK3/AKT/mTOR, which was identified as a significant
pathway by our analyses, supports the potential use of everolimus
in patients identified as high-risk.25, 26 Interestingly, 278/352
(78.9%) of patients identified as Basal-like were classified as high-
risk by our gene signature despite being clinically classified as ER+;
highlighting the need to recognize the importance of molecular
heterogeneity among the hormone receptor-positive cancers, and
the implications for novel treatment.
We have demonstrated that a novel 95-gene signature of
residual risk, which integrates nodal status, has significantly better
clinical utility for early recurrence than the currently available
multiparametric tests. The signature appears to remain prognostic
for later recurrence, though confirmation of its prognostic ability
should be evaluated upon longer follow-up. Unlike these tests,
modular analysis of the genes in the signature, have identified
several genes and pathways suitable for therapeutic intervention
among the high-risk patients. While the clinical potential of novel
therapeutic targets identified in this study are being investi-
gated,27 both additional independent clinical validation of the
signature and preclinical validation of the effects of targeting
these pathways are required prior to implementation of this
approach in a clinical trial. It is clear, however, that there is a need
for significant improvement in the targeted selection of patients
suitable for new therapies, rather than the randomization of all-
comers in future clinical trial design. As we have demonstrated,
hormone-receptor positive cancers are molecularly heteroge-
neous, thus requiring novel treatment strategies (Fig. 2a and
Supplementary Table 3, Supplementary Table 6). Clearly a
multiparametric gene signature, as we have shown here is one
means of selection, but improved stratification must also include
the integration of gene mutational and copy-number status.
Therefore we propose that in order to improve the clinical
management of women with early hormone-receptor positive
breast cancer, future clinical trial design requires a multiparametric
test that not only improves identification of high-risk patients, but
also improves the selection of patients to existing therapeutics
targeting key genes/pathways that underlies the signature.
MATERIALS AND METHODS
The TEAM trial was a multinational, open-label, phase III trial in which
postmenopausal women with hormone receptor-positive19 early breast
cancer were randomly assigned to receive exemestane (25mg) once daily,
or tamoxifen (20mg) once daily for the first 2.5–3 years; followed by
exemestane (25mg) (totaling 5 years of treatment) (Supplementary Fig. 8).
Hormone-receptor (ER and PgR) and HER2 status by immunohistochem-
istry were locally assessed for entry into the trial and then centrally
confirmed,28 and HER2 status was confirmed by immunohistochemistry
and fluorescence in situ hybridization.29 All assessment was performed
according to American Society of Clinical Oncology (ASCO)/College of
American Physicians (CAP)/ guidelines.30–32 None of the patients received
anti-HER2 therapy. This study complied with the Declaration of Helsinki,
Institutional Ethics Committee Guidelines, and the International Con-
ference on Harmonisation and Good Clinical Practice guidelines. All
patients provided informed consent. DRFS was defined as time from
randomization to distant relapse or death from breast cancer.19
The TEAM trial included a pathology research study comprised of 4736
patients from five countries with an average clinical follow-up of 6.86 years.
Power analysis was performed to confirm the study size had 88.6 and
100% power to detect a HR of at least 3.0 in the training and validation
cohorts respectively (Supplementary Figure 8B). RNA was available and
successfully assayed from 3825 samples. Patients from the UK cohort were
assigned as the training cohort (n = 790); while the remaining patients
from Germany, Belgium, Netherlands, and Greece comprised a fully-
independent validation cohort (n = 3035). All patients were assayed for
mRNA abundance (Supplementary Fig. 8C). To identify a signature of
residual risk following endocrine treatment only, the main analyses
excluded those patients who received neo-adjuvant and adjuvant
chemotherapy. However, analyses of patients who also received adjuvant
chemotherapy using the signature trained in the absence of chemotherapy
are discussed and included in the Supplementary Results.
RNA extraction and expression profiling
Five 4 µm formalin-fixed paraffin-embedded (FFPE) sections per case were
deparaffinised, tumor areas were macro-dissected and RNA extracted
using the Ambion® Recoverall™ Total Nucleic Acid Isolation Kit-RNA
extraction protocol (Life TechnologiesTM, Ontario, Canada). RNA aliquots
were quantified using a Nanodrop-8000 spectrophometer (Delaware, USA).
All 3825 RNAs extracted from the TEAM pathology cohort were
successfully assayed. Probes for each gene were designed and synthesized
at NanoString® Technologies (Seattle, Washington, USA); and 250 ng of
RNA for each sample were hybridized, processed and analyzed using the
NanoString® nCounter® Analysis System, according to NanoString®
Technologies protocols.
mRNA abundance analysis and survival modeling
Raw mRNA abundance count data were pre-processed using the
NanoStringNorm R package33 (v1.1.19) using normalization factors derived
from the geometric mean of the top expressing 75 genes. Samples with
RNA content |z-score| >6 were flagged and removed as outliers. To assess
the performance of the chosen normalization method in this cohort, a
combination of 252 preprocessing methods were evaluated. Firstly, each
preprocessing method was ranked based on their ability to maximize
Euclidean distance of ERBB2 mRNA abundance between HER2-positive and
HER2-negative samples. The process was repeated for one million random
subsets of HER2-positive and HER2-negative samples for each of the
preprocessing schemes. Fifteen replicates of an RNA pool extracted from
selected anonymized FFPE breast tumor samples were profiled across
multiple batches; and preprocessing methods were ranked based on the
inter-replicate variation. A mixed effects linear model was fit and residual
Molecular stratification of early breast cancer
J Bayani et al
8
npj Breast Cancer (2017)  3 Published in partnership with the Breast Cancer Research Foundation
estimates were used as an estimate of inter-batch variation (nlme
v3.1–117). Cumulative ranks based on these two criteria were calculated
using RankProduct and the method chosen was amongst the top 10
preprocessing methods in rank product (Supplementary Data, Supple-
mentary Fig. 9).
Univariate survival analysis of preprocessed mRNA abundance data was
performed by median-dichotomizing patients into high-expressionand
low-expression groups. Clinical variable age was modeled as binary
(dichotomized around age 55), while grade and nodal status were
modeled as ordinal variables, and pathological size was modeled as a
continuous variable.
Network-based signature derivation
Feature-selection of genes was first performed based on univariate Cox
proportional hazards modeling in the endocrine-treated only training
cohort; those with p < 0.25 were retained. These retained genes were used
to calculate a “module-dysregulation score” (MDS; Supplementary Data). A
multivariate Cox proportional hazards model was then fit on MDSs, along
with clinical covariates (age, grade, pathological size and nodal status); a
stepwise backward selection approach using Akaike Information Criterion
was performed to refine the multivariate model. The final selected model
was trained in the training cohort and validated in the fully independent
validation cohort (Table 1). DRFS truncated to 10 years was used as an end-
point. Recurrence probabilities were estimated as described in Supplemen-
tary Data. All survival modeling was performed on DRFS, in the R statistical
environment with the survival package (v2.37–4). Model performances
were evaluated through area under the receiver operating characteristic
(ROC) curve (AUC, Supplementary Data).
Derivation of commercially-based and academically-based risk
stratification scores
The derivation of similar risk classifications using genes comprising the
following multi-parametric tests OncotypeDx® (Genomic Health Inc.),5, 6
Prosigna™(NanoString Technologies, Inc.),7–9 MammaPrint® (Agendia
Inc.),10, 11 Genomic Grade Index34; in addition to IHC435, 36 are described
previously by Prat et al.,18 and in the Supplementary Data and
Supplementary Table 7.
Pathway analyses using reactome
The final gene list was loaded into the Cytoscape Reactome FI plugin in
Cytoscape (v3.0.2). Symbols were loaded as a gene set with the 2013
version of the FI network. A FI network was constructed with FI annotations
and no linker genes. Spectral clustering and pathway enrichment were
computed for each module using the Reactome FI plugin functions.
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